PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 69.82

Change

+0.61 (+0.88)%

Market Cap

N/A

Volume

3.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.11%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-0.78 (-0.71%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.33 (-0.37%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.03 (+0.12%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.02 (+0.06%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.11 (-0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.02 (-0.06%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.70 (+1.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.05 (+0.18%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.04% 14% F 44% F
Dividend Return 0.05% 13% F 1% F
Total Return 6.09% 14% F 35% F
Trailing 12 Months  
Capital Gain 24.79% 76% C+ 62% D
Dividend Return 0.06% 11% F 1% F
Total Return 24.85% 76% C+ 54% F
Trailing 5 Years  
Capital Gain 46.62% 48% F 68% D+
Dividend Return 0.10% 11% F 1% F
Total Return 46.72% 48% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.08% N/A N/A 59% D-
Dividend Return 6.09% N/A N/A 51% F
Total Return 0.01% N/A N/A 1% F
Risk Return Profile  
Volatility (Standard Deviation) 21.01% N/A N/A 49% F
Risk Adjusted Return 28.99% N/A N/A 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike